1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
153.33%
Revenue growth above 1.5x AGEN's 24.65%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
73.30%
Positive gross profit growth while AGEN is negative. John Neff would see a clear operational edge over the competitor.
-15.23%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-15.23%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-9.33%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-5.41%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-8.33%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
2.98%
Share reduction more than 1.5x AGEN's 7.64%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
2.03%
Diluted share reduction more than 1.5x AGEN's 7.64%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-36.10%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-34.66%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
95.84%
Positive long-term OCF/share growth while AGEN is negative. John Neff would see a structural advantage in sustained cash generation.
71.82%
5Y OCF/share CAGR above 1.5x AGEN's 40.16%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
66.77%
3Y OCF/share CAGR above 1.5x AGEN's 32.35%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
96.67%
Positive 10Y CAGR while AGEN is negative. John Neff might see a substantial advantage in bottom-line trajectory.
77.76%
5Y net income/share CAGR above 1.5x AGEN's 9.10%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
53.48%
Positive short-term CAGR while AGEN is negative. John Neff would see a clear advantage in near-term profit trajectory.
61.16%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-44.17%
Negative 5Y equity/share growth while AGEN is at 73.57%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
152.11%
3Y equity/share CAGR above 1.5x AGEN's 87.65%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while AGEN invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-9.40%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-0.77%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
8.30%
R&D dropping or stable vs. AGEN's 271.20%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
28.80%
SG&A growth well above AGEN's 38.28%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.